Tag: B-cell lymphomas
European Commission Approves Label Variation for Brentuximab Vedotin
The European Commission (EC) has, earlier this week, approved a Type II variation for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include data on the...
Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...
Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy. Oral...
Analysis of Phase III AETHERA Data Demonstrates Brentuximab Vedotin Consolidation Therapy...
Several new analysis of Phase III data from the AETHERA trial (NCT01100502) demonstrate that brentuximab vedotin (Adcetris®; Seattle Genetics) consolidation therapy significantly extends progression-free...
